Connect your AI

CalAmp CAMP Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Ionis PharmaceuticalsIONS

——

CytomX TherapeuticsCTMX

——

Sarepta Therapeutics, Inc.SRPT

——

Septerna, Inc.SEPN

——

Recursion Pharmaceuticals, Inc.RXRX

——

Other financials

Income statement

Revenue$1.3M+50.8%

Operating income-$13.1M+0.2%

Net income-$18.3M-47.4%

EPS (diluted)-$0.32+48.4%

Balance sheet

Cash & equivalents$100.8M+97.9%

Total debt$2.1M-73.2%

Total equity$30.9M-40.1%

Total assets$105.5M+68.0%

Cash flow

Operating cash flow-$11.0M+23.1%

CapEx--100%

Free cash flow-$11.0M+24.6%

Valuation

Market cap$226.92M+666%

Enterprise value$128.2M-3,860%

P/S57.7×+47.8×

Profitability

Operating margin-1,335.2%-512pp

Net margin-2,193.7%-581pp

FCF margin-1,254%—

Returns & leverage

Return on equity-209.3%—

Debt / equity0.1×-0.1×

Current ratio6.1×-1.9×

Where this comes from

Reported directly by CalAmp in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: CalAmp’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CalAmp's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CalAmp's deferred revenue, net of current portion?: CalAmp (CAMP) reported deferred revenue, net of current portion of $5.22M in Q1 2026.